Concepedia

Publication | Open Access

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

DOIFull Paper Access

37

Citations

45

References

2023

Year

Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa,
Journal of Thoracic Oncology

Abstract

Our findings reveal that MUC1-C is a common effector of osimertinib resistance and is a potential target for the treatment of osimertinib-resistant NSCLCs.

References

YearCitations

Page 1